Apyx Medical (APYX) Stock Price, News & Analysis

Company Overview

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions. Its surgical devices are designed to enhance hemostasis, dissection and ablation in minimally invasive and open procedures, while its Renuvion system has gained adoption in cosmetic surgery for skin contraction and soft-tissue coagulation. The company supports its products with a combination of clinical training programs, customer service and collaborative research initiatives aimed at demonstrating safety and efficacy in various treatment settings.

Established in early 2021 through a strategic combination of assets acquired from Bovie Medical, Apyx Medical has pursued a growth strategy centered on innovation and targeted commercial expansion. The company operates its headquarters in Clearwater, Florida, and maintains manufacturing and distribution capabilities to support an expanding global footprint. Guided by a leadership team with experience in medical technology and regulatory affairs, Apyx Medical continues to invest in product development and clinical evidence to broaden its treatment applications and enhance patient outcomes.

Key Stats

• Today's Range: $4.45 to $4.80
• 50-Day Range: $2.79 to $4.86
• 52-Week Range: $1.59 to $5.08
• Volume: 195,895 shs
• Average Volume: 157,073 shs
• Market Capitalization: $187.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Moderate Buy

Apyx Medical Stock Analysis - MarketRank™

Apyx Medical scored higher than 61% of companies evaluated by MarketBeat, and ranked 365th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Apyx Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Apyx Medical has a consensus price target of $6.50, representing about 45.4% upside from its current price of $4.47.

Amount of Analyst Coverage

Apyx Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Apyx Medical is -20.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apyx Medical is -20.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apyx Medical has a P/B Ratio of 11.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of Apyx Medical has been sold short.

Short Interest Ratio / Days to Cover

Apyx Medical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apyx Medical has recently decreased by 34.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apyx Medical does not currently pay a dividend.

Dividend Growth

Apyx Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.62

News Sentiment

Apyx Medical has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Apyx Medical this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Apyx Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Apyx Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.20% of the stock of Apyx Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.33% of the stock of Apyx Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/30/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:APYX
• CIK: 719135
• Web: www.apyxmedical.com
• Phone: (727) 384-2323
• Fax: 800-323-1640
• Employees: 270
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Apyx Medical: $6.50
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +45.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.21 million
• Net Margins: -16.40%
• Pretax Margin: -15.58%
• Return on Equity: -88.47%
• Return on Assets: -14.94%

Debt

• Debt-to-Equity Ratio: 2.68
• Current Ratio: 5.80
• Quick Ratio: 4.79

Sales & Book Value

• Annual Sales: $55.90 million
• Price / Sales: 3.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 11.46

Miscellaneous

• Outstanding Shares: 41,874,000
• Free Float: 35,509,000
• Market Cap: $187.18 million
• Optionable: Optionable
• Beta: 1.39